What is the best approach to take when expanding to the EU market from the US and vice versa? To what extent do the MDR and FDA overlap and what are the key differences and similarities between them? How can you plan an effective strategy for entering new markets that allows you to avoid extra costs and reduces effort? 

The different regulatory requirements between the EU and US markets can be a significant stumbling block for medical device manufacturers who plan an expansion across the pond.  In this article, prepared in cooperation with Krzysztof Minicki, our Director of Healthcare and Life Sciences, we compare the EU MDR and FDA and discuss the optimal approach for releasing a medical device to both markets.  

What are the differences and similarities between the EU MDR and FDA regulations? 

קיימים מספר הבדלים בין דרישות ה-FDA ל-MDR, אך גם כמה קווי דמיון בתחומים מסוימים. החשובים שבהם מפורטים להלן. 

Our experts will help you prepare a Technical File

גלו עוד

סיווג מכשירים רפואיים 

Under the EU MDR, there are classes I, II (further divided into IIa and IIb) and III.  The higher the class – the higher the risk. Class I includes medical devices of low risk to users (non-sterile and non-measuring devices) as well as devices of a slightly higher risk, but which are non-invasive (sterile and measuring devices). Class IIa includes middle-risk devices and class IIb – middle- to high-risk devices. Class III devices pose the highest risk to patients or operators. They are described as those which connect directly with the Central Circulatory or Nervous System or contain a medicinal product. 

Medical device classification - 1
Medical device classification - 2
Medical device classification - 3

The approach to medical device classification under the FDA is quite similar to the MDR. The FDA also classifies medical devices according to their risk level and regulatory controls necessary to ensure patient and operator safety: class I is associated with the least risk, class II with moderate risk and class III with the highest risk.  

However, there may be differences between the MDR and FDA in assessing the risk level. The MDR Class I sterile or measuring devices may be regarded as class II under the FDA’s regulation. Certain MDR class IIb medical devices could be regarded as class III according to the FDA. Each case should be assessed independently.  

קריאה מומלצת: 

מערכות ניהול איכות 

Both the MDR and FDA require manufacturers of medical devices, including software, to have a Quality Management System implemented that is compliant with respective regulations. 

היקף התוכן 

The FDA differs from the EU MDR in scope and how the information is organised. The FDA regulations are divided into sections according to the categories of medical devices. Each section includes requirements regarding the safety and effectiveness of medical devices as per their use. It’s directly connected to the premarket submission method followed later in the process.  

The MDR focuses more on the specific requirements for medical device manufacturers and notified bodies who overview the process of introducing new medical devices to the EU market. The MDR also includes many definitions and detailed information on financial liabilities and penalties, which aren’t within the scope of the FDA regulations.  

תהליך הגשה 

על פי ה-FDA וה-MDR, מכשירים רפואיים מסוג class I (בעלי הסיכון הנמוך ביותר, שאינם מודדים ואינם סטריליים) אינם נדרשים לעבור ביקורת בלתי תלויה לפני שחרורם למכירה. כדי להציגם בשווקי האיחוד האירופי וארצות הברית, על היצרנים לפעול לפי תהליך הצהרה עצמית (באיחוד האירופי זהותהליך סימון CEמטבע הדברים, יש להכין את כל התיעוד המתאים, אך אין צורך באימות של צד שלישי. 

מכשירים רפואיים בסיכון גבוה יותר חייבים להיות מאומתים על ידי גוף notified באיחוד האירופי או על ידי ה-FDA בארה"ב. בשני המקרים יש להכין תיק טכני, אף שתהליך השחרור לשוק שונה. 

קריאה מומלצת: How to get FDA approval for medical devices? 

The most common submission method under the FDA regulations is a Premarket Notification 510(k). Once you deliver all the necessary documentation, the FDA audits and verifies your submission. Under the EU MDR, the audit is related to the review of the Quality Management System, which is regulated by ISO 13485. The norm is harmonised, which means that it specifies certain legal requirements that need to be applied to achieve compliance . In other words, the compliance requirements can only be met if the norm is implemented in your organisation.  

A medical device manufacturer who wants to introduce their product to the EU market for the first time needs to get certified in ISO 13485 beforehand. The certification process includes a two-stage audit. The first stage is the review of the processes and procedures related to the Quality Management System’s compliance with ISO 13485 and associated regulations (such as IEC 62304, ISO 14971, etc.). In the second stage, the technical documentation, including the Technical File of a medical device is reviewed to ensure its compliance with appropriate processes. However, under the MDR the review is only selective, while FDA conducts a full audit.  

As per both the MDR and the FDA regulations, the medical device manufacturers are required to maintain control and ensure that a medical device will continue to be safe to use according to its Intended Use after it’s been released to market.  

מאגרי נתונים של מכשירים רפואיים 

There are different medical device databases functioning in the EU and the US, where all the information about the class of a medical device, its Intended Use, etc. are stored. In the US, it’s the מאגר המכשירים הרפואיים של ה-FDA ובאיחוד האירופי – EUDAMED. They are separate and independent from each other.  

מערכת זיהוי ייחודית למכשירים רפואיים 

UDI is a globally accepted system and applies in the EU as well as in the US. The MDR expanded the concept of UDI by introducing the UDI-DI identification that allows for the grouping medical of devices that have the same intended purpose, risk class, essential design and manufacturing characteristics. However, there are certain differences between the MDR and FDA as to where and how the labels should be placed on medical devices.  

תיעוד טכני 

למרות העובדה שלתקנות ה-FDA וה-MDR בנוגע לתיק הטכני (Technical File) יש קווי דמיון מסוימים, אין זה אומר שתיק טכני שהוכן לפי דרישות האיחוד האירופי יהיה מקובל באותה מידה בארצות הברית, ולהיפך. חלק מההבדלים טמונים בניואנסים הנוגעים לייצור מכשירים רפואיים, כגון ניהול סיכונים וסיווג. 

For example, the FDA requires additional classification that defines Level of Concern. It doesn’t exist in the MDR regulation. It may be an obstacle for companies who already sell their medical devices on the EU market and now want to introduce their products to the US market. 

What’s the right approach in such a case? When preparing technical documentation, you should include all the markets where you plan to sell your medical device. The market-specific information, for instance, regarding the aforementioned Level of Concern, should be included in the appropriate chapters of the documentation.  

In other words, your documentation should cover the requirements specified in both the FDA and MDR. It’s not only the best possible, but also recommended, approach.  

הערכה קלינית 

עבור כל מכשירים רפואיים מסוג class III וחלק ממכשירי class IIb, תקנת ה-EU MDR דורשת הכנת דוח הערכה קלינית (CER) על ידי היצרן, שלאחר מכן נבדק ומאושר על ידי גוף מוסמך (Notified Body). לעומת זאת, ה-FDA אינו דורש CER עבור רוב המכשירים הרפואיים הכשירים להגשה במסלול 510(k). 

שמישות של מכשירים רפואיים 

Both the FDA and the EU MDR put a strong focus on the usability of medical devices. Under the FDA, this concept is reflected by the Human Factors Studies. Human Factors Studies consist of two stages, formative and summative, and its goal is to check the usability and safety of software as a medical device (SaMD). The formative stage takes place at the beginning of the software development process, when wireframes and a proof of concept are created. The summative stage takes place at the end of the development process.  

Our experts will help you prepare a Technical File compliant with the FDA and MDR 

Preparing a single Technical File, compliant with both the FDA and MDR upfront, will save you extra costs compared to preparing a separate Technical File per each regulation. It’s worth planning the target markets for your medical device ahead of time.  

Our consultants will assist you in preparing all the necessary technical documentation to meet the requirements of the EU and US medical device market. We’ll also help you get certified in ISO 13485, ISO 14971 or IEC 62304.  

ראה את עמוד ההצעה של תחום הבריאות ומדעי החיים for more details or contact Krzysztof Minicki directly using the form below.  

The key difference lies in their regulatory frameworks – the EU Medical Device Regulation (MDR) is governed by European legislation applicable across all EU member states, while the U.S. Food and Drug Administration (FDA) operates under U.S. federal law. MDR emphasises documentation and post-market surveillance, whereas the FDA focuses on premarket approval processes and clinical performance.

The EU MDR categorises medical devices into four risk-based classes: Class I, IIa, IIb and III, with increasing regulatory scrutiny. The FDA uses three classes: Class I (low risk), Class II (moderate risk) and Class III (high risk). Although both systems are risk-based, the classification criteria and resulting regulatory pathways differ considerably.

Both regulatory systems prioritise patient safety, product performance and risk management. They require manufacturers to conduct clinical evaluations, implement quality management systems and carry out post-market surveillance. Additionally, both systems support a lifecycle approach to device regulation.

In the EU, conformity assessments are conducted by Notified Bodies, which are independent organisations designated by member states. In the US, the FDA directly reviews and approves or clears medical devices, particularly through pathways such as 510(k), PMA or De Novo classifications.

Under the EU Medical Device Regulation (MDR), clinical evaluation is an ongoing process throughout the device lifecycle, with a particular focus on real-world clinical data and post-market clinical follow-up (PMCF). By contrast, the FDA places greater emphasis on pre-market clinical trials, particularly for high-risk devices under the PMA pathway.